Literature DB >> 19043414

Molecular basis of Pirh2-mediated p53 ubiquitylation.

Yi Sheng1, Rob C Laister, Alexander Lemak, Bin Wu, Elizabeth Tai, Shili Duan, Jonathan Lukin, Maria Sunnerhagen, Sampath Srisailam, Murthy Karra, Sam Benchimol, Cheryl H Arrowsmith.   

Abstract

Pirh2 (p53-induced RING-H2 domain protein; also known as Rchy1) is an E3 ubiquitin ligase involved in a negative-feedback loop with p53. Using NMR spectroscopy, we show that Pirh2 is a unique cysteine-rich protein comprising three modular domains. The protein binds nine zinc ions using a variety of zinc coordination schemes, including a RING domain and a left-handed beta-spiral in which three zinc ions align three consecutive small beta-sheets in an interleaved fashion. We show that Pirh2-p53 interaction is dependent on the C-terminal zinc binding module of Pirh2, which binds to the tetramerization domain of p53. As a result, Pirh2 preferentially ubiquitylates the tetrameric form of p53 in vitro and in vivo, suggesting that Pirh2 regulates protein turnover of the transcriptionally active form of p53.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19043414      PMCID: PMC4075976          DOI: 10.1038/nsmb.1521

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  35 in total

1.  Latent and active p53 are identical in conformation.

Authors:  A Ayed; F A Mulder; G S Yi; Y Lu; L E Kay; C H Arrowsmith
Journal:  Nat Struct Biol       Date:  2001-09

2.  Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases.

Authors:  N Zheng; P Wang; P D Jeffrey; N P Pavletich
Journal:  Cell       Date:  2000-08-18       Impact factor: 41.582

3.  Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.

Authors:  Roger P Leng; Yunping Lin; Weili Ma; Hong Wu; Benedicte Lemmers; Stephen Chung; John M Parant; Guillermina Lozano; Razqallah Hakem; Samuel Benchimol
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

Review 4.  The p53-Mdm2 module and the ubiquitin system.

Authors:  Dan Michael; Moshe Oren
Journal:  Semin Cancer Biol       Date:  2003-02       Impact factor: 15.707

5.  Refinement of protein structures in explicit solvent.

Authors:  Jens P Linge; Mark A Williams; Christian A E M Spronk; Alexandre M J J Bonvin; Michael Nilges
Journal:  Proteins       Date:  2003-02-15

6.  Sequence specific resonance assignment via Multicanonical Monte Carlo search using an ABACUS approach.

Authors:  Alexander Lemak; Carlos A Steren; Cheryl H Arrowsmith; Miguel Llinás
Journal:  J Biomol NMR       Date:  2008-05-06       Impact factor: 2.835

7.  Structure and functionality of a designed p53 dimer.

Authors:  T S Davison; X Nie; W Ma; Y Lin; C Kay; S Benchimol; C H Arrowsmith
Journal:  J Mol Biol       Date:  2001-03-23       Impact factor: 5.469

8.  The ubiquitin ligase COP1 is a critical negative regulator of p53.

Authors:  David Dornan; Ingrid Wertz; Harumi Shimizu; David Arnott; Gretchen D Frantz; Patrick Dowd; Karen O'Rourke; Hartmut Koeppen; Vishva M Dixit
Journal:  Nature       Date:  2004-04-21       Impact factor: 49.962

9.  Structural model of the UbcH5B/CNOT4 complex revealed by combining NMR, mutagenesis, and docking approaches.

Authors:  Cyril Dominguez; Alexandre M J J Bonvin; G Sebastiaan Winkler; Frederik M A van Schaik; H Th Marc Timmers; Rolf Boelens
Journal:  Structure       Date:  2004-04       Impact factor: 5.006

Review 10.  Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.

Authors:  Patrick Chène
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

View more
  52 in total

1.  Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Authors:  Jonathan Shloush; John E Vlassov; Ian Engson; Shili Duan; Vivian Saridakis; Sirano Dhe-Paganon; Brian Raught; Yi Sheng; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

Review 2.  Making sense of ubiquitin ligases that regulate p53.

Authors:  Abhinav K Jain; Michelle Craig Barton
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

3.  Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.

Authors:  Rui Kamada; Takao Nomura; Carl W Anderson; Kazuyasu Sakaguchi
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

4.  Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.

Authors:  Chad A Corcoran; JoAnne Montalbano; Hong Sun; Qin He; Ying Huang; M Saeed Sheikh
Journal:  J Biol Chem       Date:  2009-05-29       Impact factor: 5.157

5.  TRIMming p53 for ubiquitination.

Authors:  Elizabeth Tai; Samuel Benchimol
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-07       Impact factor: 11.205

6.  The three-dimensional structure of an H-superfamily conotoxin reveals a granulin fold arising from a common ICK cysteine framework.

Authors:  Lau D Nielsen; Mads M Foged; Anastasia Albert; Andreas B Bertelsen; Cecilie L Søltoft; Samuel D Robinson; Steen V Petersen; Anthony W Purcell; Baldomero M Olivera; Raymond S Norton; Terje Vasskog; Helena Safavi-Hemami; Kaare Teilum; Lars Ellgaard
Journal:  J Biol Chem       Date:  2019-04-11       Impact factor: 5.157

7.  A new era of studying p53-mediated transcription activation.

Authors:  Wei-Li Liu; Robert A Coleman; Sameer K Singh
Journal:  Transcription       Date:  2017-10-04

8.  Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation.

Authors:  Yong-Sam Jung; Gang Liu; Xinbin Chen
Journal:  Mol Cell Biol       Date:  2009-12-14       Impact factor: 4.272

Review 9.  The ubiquitin proteasome system in neuropathology.

Authors:  Norman L Lehman
Journal:  Acta Neuropathol       Date:  2009-07-14       Impact factor: 17.088

10.  Bi-directional SIFT predicts a subset of activating mutations.

Authors:  William Lee; Yan Zhang; Kiran Mukhyala; Robert A Lazarus; Zemin Zhang
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.